About the Audacious Goals Initiative & the National Eye Institute (NEI)
Age-related macular degeneration is the leading cause of vision loss in the US, affecting 2.5% of the population, most over the age of 50. There are no promising treatment options to slow the progression of AMD, and at present there is no way to stop or reverse the disease course. The most common advanced type of AMD in United States is the dry form of the disease, affecting 80-90% individuals with AMD. There is no approved treatment or cure for dry AMD.
In the advanced stages of the disease, AMD destroys retinal pigment epithelium (RPE) cells in the retina. Because of the cellular loss, therapies that replace the destroyed RPE cells are being investigated as a way to restore vision. One approach is to use induced pluripotent stem cells (iPSC) converted into new RPE cells that can be injected into the eye.
Researchers at the National Eye Institute (NEI) have developed a new system to deliver, under the retina (i.e. subretinal), RPE cells derived from patients own induced pluripotent stem cells. The iPSCs are differentiated into RPE cells and seeded onto a polylactic-co-glycolic acid (PGLA) scaffold. Once implanted into the eye, the PGLA scaffold slowly biodegrades, leaving behind the new RPE cells aligned in the proper orientation to integrate into the existing tissue. This would be one of the first treatments of its kind.
Building the IND Package
Covance, in collaboration with Ocular Services On Demand (OSOD), have been contributing towards the NEI’s IND submission package for this stem cell treatment by running preclinical studies, including preliminary tolerability, biodistribution, toxicity and tumorgenicity of the therapy in rat models. The Covance/OSOD team performed 2 pilot and 4 GLP studies.
Overcoming Implementation Scalability and Other Challenges
Prior to Covance studies, researchers at NEI performed some preliminary preclinical studies to develop a transplantation tool, obtain safety and efficacy data and evaluate biodistribution and tumorigenicity.
The first challenge was to demonstrate the advantage of using the scaffold patch. In the preclinical studies, the iPSC-derived RPE were delivered to the subretinal space in two ways: as a cell monolayer on scaffold implants and as cells in suspension. An initial challenge was to determine how to apply the procedures on small research models. The team was able to downsize a non-human primate implant in order to effectively test on small research models.
Safety profiles were comparable between injection and implantation arms of the study with no systemic effects. At the end of the study, viable iPSC-derived RPE were present in the subretinal space. As expected, cells on the scaffold remained localized to the region of the implant compared with those in suspension that were distributed over a larger region under the retina.
One concern with stem cell therapies is that the differentiated therapeutic cells revert back into undifferentiated cells, which could then form tumors. A positive control group consisting of undifferentiated iPSC was included in the experiment. Research models receiving subretinal injections of pure iPS cells developed teratomas, but none of the models receiving iPSC-derived RPE cells had teratomas at the end of the study.
Finally, an immunodeficient research model was needed in order to accept the test product. This required special protections and procedures to prevent the rats from acquiring pathogens that could cause pathology. The experiments were performed in an AAALAC accredited facility following IACUC approval.
Looking Ahead: Clinical Testing Challenges
As of January 2019, the NEI team is preparing its IND submission for clinical trials of the treatment.
Important aspects of conducting studies with stem cells may include special cell culture requirements, procedures to characterize the differentiated cell therapy, and methods to evaluate possible effects of the transplant on the retina. To accomplish this, appropriate laboratory facilities, equipment, validated methods as well as well-trained scientists are required. Covance has since expanded its immunotoxicology capabilities, and is growing its cell culture capabilities with the focus on handling future iPSC projects.
Note: Some of our content is gated due to its proprietary nature; create a free username/password to access.
http://stm.sciencemag.org/content/11/475/eaat5580 [Science Translational Med paper]